Grant Finder

LLS investigators are outstanding scientists at the forefront of leukemia, lymphoma and myeloma research at centers throughout the world. Search to see the many research projects that LLS is currently funding.

Grant: 7016-18 | Specialized Center of Research Program (SCOR):

Location:The University of Texas MD Anderson Cancer Center, Houston, Texas 77210-4266

Year: 2018

Project Title: SCOR In High Risk Plasma Cell Dyscrasias

Project Summary:

Multiple myeloma is a cancer of plasma cells and already the second most commonly diagnosed blood-related tumor. Also, because there is an increase in the at-risk population with the aging of America, and a greater percentage of these patients appear to be developing this disease, new cases will grow by almost 60% from 2010 to 2030, ranking it third among all cancers in the rate of increase during this time.

Grant: 7017-18 | Specialized Center of Research Program (SCOR):

Location:University of Miami, Atlanta, Georgia 30384-5803

Year: 2018

Project Title: Interventional Epigenetics In Myeloid Malignancies

Project Summary:

Cancers like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) arise due to a combination of genetic mutations and epigenetic abnormalities that sustain the abnormal behavior of cancer cells. The genetic material (DNA) of the cell can be considered a “hard drive” full of instructions that allow cells to grow, have unique functions, and ultimately live or die. Epigenetics, by analogy, is the “software” of the cell, allowing access to the information from the hard disk in a controlled manner.

Grant: 6546-18 | Translational Research Program (TRP):

Location:Boston Children's Hospital, Boston, Massachusetts 02241-4413

Year: 2017

Project Title: Deciphering Epigenetic Cross-talk In Diffuse Large B-cell Lymphoma

Project Summary:

With an estimated 73,000 new cases of non-Hodgkin lymphoma (NHL) and 20,000 deaths in the year 2016 alone from NHL, novel therapeutic strategies are urgently required. Specifically, the diffuse large B-cell lymphoma (DLBCL) is the most common form of NHL, and contributes about 30% of new NHL diagnosis every year. Our interest in blood biology, and its mis-regulation is several blood disorders including blood cancers, led us to investigate the role of chemical modifications on one of the most fundamental proteins of like- the histone proteins.

Grant: 1349-18 | Career Development Program (CDP):

Location:Washington University School of Medicine in St. Louis, St. Louis, Missouri 63112-1408

Year: 2017

Project Title: Protection Of Proliferating B Lymphocytes From Transformation By A C-MYC-induced Tumor Suppressive Program

Project Summary:

Lymphomas and leukemias are caused by uncontrolled proliferation of lymphocytes due to accumulating errors in the genome. However, cell proliferation is also an important biological activity across many different tissues and cell types. Specifically, proliferation of lymphocytes is essential for the immune responses that protect individuals from invading pathogens. Normal lymphocytes are able to proliferate even quicker than cancer cells in response to infection for extended periods of time.

Grant: 6533-18 | Translational Research Program (TRP):

Location:Sloan Kettering Institute for Cancer Research, New York, New York 10087

Year: 2017

Project Title: Chemotherapy-Free Targeted Therapeutic Approaches For New And Relapsed Hairy Cell Leukemia

Project Summary:

Classic hairy cell leukemia (cHCL) is a relatively rare form of adult blood cancer that causes massive enlargement of spleen and low white blood, red or platelet cell count.  It remains incurable despite high initial response rates to DNA-damaging chemotherapy such as cladribine and pentostatin, and 40% of the patients will experience recurrent disease.

Grant: 3378-18 | Career Development Program (CDP):

Location:Sloan Kettering Institute for Cancer Research, New York, New York 10087

Year: 2017

Project Title: Optimizing CAR T Cell Therapy For Multiple Myeloma

Project Summary:

While advances have recently been made in the management of multiple myeloma (MM), MM is still considered incurable, with most patients dying from their disease. Thus, there is a critical need to identify and evaluate new therapeutic modalities that may induce durable remissions or cures.

Grant: 5469-18 | Career Development Program (CDP):

Location:Joan & Sanford I. Weill Medical College of Cornell University, New York, New York 10022

Year: 2017

Project Title: Mutations Disrupting Gene Enhancer Epigenetic Complexes As Drivers Of Lymphomagenesis.

Project Summary:

Lymphoma is a form of cancer that affects immune cells called lymphocytes, a type of white blood cell. There are many subtypes and maturation stages of lymphocytes and, therefore, many kinds of lymphomas. Follicular lymphomas (FL) develop from B lymphocytes (B-cells) and are the second most common subtype of non-Hodgkin lymphoma. Clinically, FL is an indolent lymphoma, characterized by slow progression and relatively high overall survival rate.

Grant: 5463-18 | Career Development Program (CDP):

Location:La Jolla Institute for Allergy and Immunology, La Jolla, California 92037

Year: 2017

Project Title: TET Proteins In B Cell Function And Malignancy.

Project Summary:

DNA methylation is a fundamental biological process that controls the activation state of genes, which represent basic modules of biological systems. TET proteins were recently identified as enzymes that mediate the removal of DNA methylation and have been shown to play vital roles in normal development of organisms. Moreover, the activity of TET enzymes is often deregulated during the pathogenesis of various hematological and non-hematological cancers.

Grant: 3376-18 | Career Development Program (CDP):

Location:The University of Utah, Salt Lake City, Utah 84112-9003

Year: 2017

Project Title: Determining The Role Of SIRT5 In Acute Myeloid Leukemia

Project Summary:

Acute myeloid leukemia (AML) is the most deadly blood cancer, with more than 70% of patients dying from the disease within five years after diagnosis. The treatment option shave remained largely unchanged for the past 30 years. Chemotherapy and stem cell transplant are still the standard therapy for AML. The fact that most patients with AML will eventually relapse and succumb to their disease defines an urgent, unmet medical need for more effective drugs to treat this disease. To answer this call, we have taken a novel approach to identify new drug targets.

Grant: 6543-18 | Translational Research Program (TRP):

Location:Children's Research Institute, Washington, District of Columbia 20010

Year: 2017

Project Title: Novel Combination Immunotherapies For High Risk Hodgkin's Lymphoma

Project Summary:

Hodgkin’s lymphoma (HL), a type of blood cancer is largely curable but with significant long-term side effects. Moreover 10-20% of patients are resistant to treatment and difficult to cure. HL is unique that the tumor cells are surrounded by an inhibitory environment that makes the immune system dysfunctional and allows evasion from an effective anti-tumor response. Understanding this environment may provide insight into how we can spur the immune system to attack HL cells effectively.

Pages